Literature DB >> 23205289

Advanced lung cancer in the older patient: is there a role for bevacizumab?

Alissa S Marr1, Apar Kishor Ganti.   

Abstract

Entities:  

Year:  2012        PMID： 23205289      PMCID： PMC3506784          DOI： 10.3978/j.issn.2072-1439.2012.09.07

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  6 in total

1.  Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial.

Authors:  Elisabeth Quoix; Gérard Zalcman; Jean-Philippe Oster; Virginie Westeel; Eric Pichon; Armelle Lavolé; Jérôme Dauba; Didier Debieuvre; Pierre-Jean Souquet; Laurence Bigay-Game; Eric Dansin; Michel Poudenx; Olivier Molinier; Fabien Vaylet; Denis Moro-Sibilot; Dominique Herman; Jaafar Bennouna; Jean Tredaniel; Alain Ducoloné; Marie-Paule Lebitasy; Laurence Baudrin; Silvy Laporte; Bernard Milleron
Journal:  Lancet       Date:  2011-08-08       Impact factor: 79.321

2.  Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer.

Authors:  Alan Sandler; Jing Yi; Suzanne Dahlberg; Margaret M Kolb; Lisa Wang; Julie Hambleton; Joan Schiller; David H Johnson
Journal:  J Thorac Oncol       Date:  2010-09       Impact factor: 15.609

3.  Effectiveness and safety of bevacizumab for unresectable non-small-cell lung cancer: a meta-analysis.

Authors:  Kun Yang; You-Juan Wang; Xue-Rong Chen; Hai-Ning Chen
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

4.  Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer.

Authors:  Junya Zhu; Dhruv B Sharma; Stacy W Gray; Aileen B Chen; Jane C Weeks; Deborah Schrag
Journal:  JAMA       Date:  2012-04-18       Impact factor: 56.272

5.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

Authors:  Alan Sandler; Robert Gray; Michael C Perry; Julie Brahmer; Joan H Schiller; Afshin Dowlati; Rogerio Lilenbaum; David H Johnson
Journal:  N Engl J Med       Date:  2006-12-14       Impact factor: 91.245

6.  Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599.

Authors:  Suresh S Ramalingam; Suzanne E Dahlberg; Corey J Langer; Robert Gray; Chandra P Belani; Julie R Brahmer; Alan B Sandler; Joan H Schiller; David H Johnson
Journal:  J Clin Oncol       Date:  2008-01-01       Impact factor: 44.544
  6 in total
  1 in total

1.  U.S. Food and Drug Administration Approval Summary: Ramucirumab for the Treatment of Metastatic Non-Small Cell Lung Cancer Following Disease Progression On or After Platinum-Based Chemotherapy.

Authors:  Erin Larkins; Barbara Scepura; Gideon M Blumenthal; Erik Bloomquist; Shenghui Tang; Missiratch Biable; Paul Kluetz; Patricia Keegan; Richard Pazdur
Journal:  Oncologist       Date:  2015-10-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.